InvestorsHub Logo
icon url


12/27/17 9:35 AM

#120252 RE: HoosierHoagie #120250

Cannabis Market Begins to Mature in Legal News Commentary
PR NEWSWIRE 9:00 AM ET 12/27/2017
Symbol Last Price Change
GOHE 0.0755up +0.00439 (+6.17%)
OWCP 0.46up +0.025 (+5.75%)
CVSI 0.45up +0.01 (+2.27%)
CBIS 0.087up +0.0045 (+5.45%)

QUOTES AS OF 09:32:30 AM ET 12/27/2017
NEW YORK , December 27, 2017 /PRNewswire/ --

According to a report by Ameri Research Inc., the global legal cannabis market was valued at $14.3 billion in 2016 and is forecast to grow at a CAGR of 21.1% between 2017 to 2024 and culminating to $63.5 billion by 2024. The market is going through a period of strong growth thanks to increasing legalization and decriminalization of cannabis products across North America and Europe. The report indicates that legalization wave is moving beyond the U.S. region. In 2017, the Canadian prime minister has introduced a bill to legalize marijuana for recreational purposes. The proposed bill mandates the legal age for consumption of cannabis at 18 years, and provides clarity on the federal and state laws in regulating the cultivation, storage and distribution of cannabis across the country. Global Payout, Inc.(GOHE) , OWC Pharmaceutical Research Corp.(OWCP) , CV Sciences, Inc.(CVSI) , Cannabis Science, Inc.(CBIS) , United Cannabis Corporation (OTC: CNAB)

Strong sales in the cannabis market resulted in economic growth in states where sales of cannabis products are legal. The Ameri Research Inc. explains that, "Growing user base for recreational marijuana in states such as Colorado, California, Alaska, Massachusetts, Washington DC and other states is a key factor boosting the tax revenues. For instance, in 2016 Colorado reported revenues exceeding 1.1 billion from the sale of marijuana products and the tax collected from the sale of these products is diverted into specific community development projects such as the construction of schools and infrastructure development, which is anticipated to improve the overall economy of the region."

Global Payout, Inc. (GOHE) on November 28th the company announced that, "its majority owned subsidiary, MoneyTrac Technology, Inc. ("MTRAC", the "Company") has established a key strategic partnership with T&T Financial to shore-up and bolster the sales and marketing related services that MTRAC is delivering to many of the underserved businesses in the emerging cannabis industry.

Over the past several weeks, MTRAC has been working in collaboration with additional partners in the financial services sector to lay the groundwork for the banking solutions they intend to offer retailers and suppliers who are operating fully compliant businesses in cannabis. This newly executed partnership with T&T Financial will provide MTRAC with critical sales and marketing support for the banking services and solutions they will be offering to an industry that is currently in dire need of an effective and practical solution to support the massive amount of commerce that currently exists within it.

It is MTRAC's intent to position itself to launch their banking services as soon as possible as it recognizes the need for it amongst businesses will be stronger than ever in 2018 as cannabis becomes recreational in one of the nation's largest economic states, California. And as the Company moves forward with this objective, they will look to establish additional partnerships with companies, such as T&T Financial, whose existing services and solutions can be leveraged by MTRAC to develop and offer the most powerful and effective banking solution available in the industry.

T&T Financial is a full service financial services company located in Anaheim, CA, servicing the needs of business and institutional clients. The principals have a combined 40 years of experience and the firm approaches all solutions with a dynamic approach that the world constantly changes just as its tools and products should adapt to the needs."

OWC Pharmaceutical Research Corp. (OWCP) , through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. Recently, the company announced it received a new permit from the Israel Medical Cannabis Agency [MCA] to proceed with the safety study of their oral disintegrating tablet. The study protocol will be submitted to the Institutional Review Board [IRB] at a leading Israeli academic hospital in the coming weeks. The study is scheduled to start in Q2 2018. In October of 2016 OWC announced that it had completed the development of a proprietary cannabinoid-enriched sublingual tablet (the "Tablet") for the administration of medical cannabis. The Tablet constitutes a smoke-free alternative for patients using medical cannabis.

CV Sciences, Inc. (CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. On November 14, 2017, the company announced it has been named on Deloitte's Technology Fast 500™, an annual ranking of the fastest growing companies in the technology, media, telecommunications, life sciences and energy tech sectors in North America. The Deloitte Technology Fast 500 is based on percentage of revenue growth from fiscal year 2013 to 2016, with CV Sciences(CVSI) growing by 403% during this period. 2017 marksCV Sciences'(CVSI) first year named on the Deloitte's Technology Fast 500™ list.

Cannabis Science, Inc. (CBIS) takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. On December 22, 2017, the company announced it has negotiated an ICO with a major asset backed Blockchain participant. This January 2018Cannabis Science(CBIS) plans pre-launch sales of our own proprietary blockchain and will commence ICO trading with a unique three symbol trading symbol on a number of blockchain currency exchange markets after pre-launch sales have completed. The Company will officially open the first two Cannabis Science PRE ICO Medical Marijuana dispensaries in the city of Los Angeles and the greater San Fernando Valley area of Los Angeles. Both dispensaries are scheduled to open at the end of this year to meet the expected increased demand in the Los Angeles market from the much-anticipated January 2018 new California recreational market influx.

United Cannabis Corp. is a biotechnology company dedicated to the development of phyto-therapeutic based products supported by patented technologies for the pharmaceutical, medical, and industrial markets. The Company has long advocated the application of cannabinoids for medical applications and is building a platform for designing targeted therapies to increase the quality of life for patients around the world. On December 14, 2017, the company announced that Jamaica'sMinistry of Health has approved its patent-protected Prana Medicinal Sublinguals and Prana Medicinal Transdermals for use by registered medicinal cannabis patients. The Prana Collection is the foundation of the Company's cannabis-centric formulations, which patients have found effective in providing relief from the symptoms of arthritis, neuropathy, acute pain, joint aches, muscle tension, muscle spasms, muscle recovery, migraines, and various skin conditions.

Subscribe Now! Watch us report from NYSE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For this release, has been compensated four thousand dollars for financial news dissemination and PR services by cambridge consultants for global payout, inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit:

For further information:
Media Contact: